Terminated PHASE2 INTERVENTIONAL 1-arm NCT05501574

An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients

Sponsor: Novotech (Australia) Pty Limited

Interventions Plastiape RS00 Dry Powder inhaler device Tacrolimus Inhalation Powder

Updated 7 times since 2022 Last updated: Jan 2, 2025 Started: Apr 18, 2023 Primary completion: Oct 29, 2024 Completion: Dec 23, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated due to funding constraints

Other terminated trials from Novotech (Australia) Pty Limited

More terminations from Novotech (Australia) Pty Limited

This PHASE2 trial investigates Lung Transplant Rejection and is currently terminated or withdrawn. Novotech (Australia) Pty Limited leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2023 — May 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Nov 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novotech (Australia) Pty Limited
TFF Pharmaceuticals, Inc.

Data source: TFF Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Darlinghurst, Australia
• Melbourne, Australia